Gastroenterology
Volume 137, Issue 1 , Pages 20-22 , July 2009

Evidence That Proton-Pump Inhibitor Therapy Induces the Symptoms it Is Used to Treat

  • Kenneth E.L. McColl

      Affiliations

    • Corresponding Author InformationReprint requests Address requests for reprints to: Kenneth E. L. McColl, MD, Division of Cardiovascular & Medical Sciences, University of Glasgow, Gardiner Institute, 44 Church Street, Glasgow, G11 6NT, UK
    • ,
  • Derek Gillen

  • Image Result

    The increased gastrin concentration during proton-pump inhibitor therapy exerts trophic effects on the oxyntic mucosa causing hyperplasia and increased functional capacity of the enterochromaffin-like

    The increased gastrin concentration during proton-pump inhibitor therapy exerts trophic effects on the oxyntic mucosa causing hyperplasia and increased functional capacity of the enterochromaffin-like (ECL) cell and parietal cell. As a consequence, on discontinuing the proton-pump inhibitor there is rebound acid hypersecretion which persists for at least 2 months.

 Conflicts of interest The authors disclose no conflicts.

PII: S0016-5085(09)00780-X

doi: 10.1053/j.gastro.2009.05.015

Gastroenterology
Volume 137, Issue 1 , Pages 20-22 , July 2009

Article Tools

* Image Usage & Resolution